Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Valsartan + celecoxib is a combination of two small molecule drugs, each with distinct mechanisms of action. Valsartan is an angiotensin II receptor blocker (ARB) used primarily to manage hypertension, heart failure, and diabetic nephropathy by selectively blocking the angiotensin II type 1 receptor, leading to vasodilation and reduced blood pressure[5]. Celecoxib is a selective cyclooxygenase-2 (COX-2) inhibitor nonsteroidal anti-inflammatory drug (NSAID), used to treat pain and inflammation in conditions such as osteoarthritis, rheumatoid arthritis, acute pain, menstrual symptoms, and familial adenomatous polyposis. It works by inhibiting COX-2 enzyme activity involved in prostaglandin synthesis[8][6]. There are no widely marketed or approved fixed-dose combinations of valsartan with celecoxib; their co-administration may occur off-label but can reduce the antihypertensive effect of valsartan and increase risk for kidney dysfunction[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on valsartan + celecoxib.